NORMOSOL-R IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NORMOSOL-R IN PLASTIC CONTAINER (NORMOSOL-R IN PLASTIC CONTAINER).

How it works

Normosol-R is an isotonic crystalloid solution that replaces extracellular fluid volume and electrolytes. It provides sodium, chloride, potassium, magnesium, acetate, and gluconate to maintain acid-base balance and osmotic equilibrium. Acetate and gluconate are metabolized to bicarbonate, providing an alkalinizing effect.

What the body does with it

Metabolism	Acetate and gluconate are metabolized primarily in the liver and tissues to bicarbonate.
Excretion	Renal excretion of electrolytes and water; no hepatic metabolism. >95% of administered water and electrolytes are excreted renally, with small amounts lost via feces (<2%) and insensible losses.
Half-life	Not applicable as a drug; the half-life of infused crystalloid components is distribution-dependent. Sodium and chloride have a terminal half-life of approximately 2-4 hours in healthy adults, reflecting renal clearance. Clinical context: Half-life prolonged in renal impairment.
Protein binding	Negligible (<1%) for electrolytes; not bound to plasma proteins.
Volume of Distribution	Sodium and chloride distribute primarily in extracellular fluid (ECF), approximately 0.2 L/kg. Clinical meaning: Expansion of ECF volume; minimal intracellular penetration.
Bioavailability	Intravenous: 100% (complete bioavailability).
Onset of Action	Intravenous: Immediate (within seconds to minutes) as plasma volume expansion and electrolyte correction begin upon infusion.
Duration of Action	Intravenous: 1-2 hours for volume expansion effect; electrolyte effects persist 2-6 hours depending on renal function. Clinical note: Duration is short, requiring continuous infusion for sustained effect.

Classification & Brands

Dosing & administration

Intravenous infusion; dose determined by electrolyte and fluid requirements; typical adult dose: 250-1000 mL/hour, not to exceed 30 mL/kg/day.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with severe renal impairment (GFR <30 mL/min/1.73 m²) due to risk of hyperkalemia and fluid overload. Use with caution and monitor serum potassium and fluid status in moderate impairment (GFR 30-60 mL/min/1.73 m²). No specific dose adjustment; rate and volume should be individualized.
Liver impairment	No specific adjustments for hepatic impairment based on Child-Pugh score; however, monitor fluid and electrolyte balance closely in patients with cirrhosis or ascites due to risk of fluid overload and electrolyte disturbances.
Pediatric use	Dose and rate based on body weight; typical infusion rate: 20-100 mL/kg/day, adjusted for maintenance or replacement needs; monitor serum electrolytes and fluid balance closely.
Geriatric use	Elderly patients may have reduced renal function; start with lower infusion rates and volumes; monitor for fluid overload and electrolyte imbalances, particularly hyperkalemia; adjust based on renal status and cardiac function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NORMOSOL-R IN PLASTIC CONTAINER (NORMOSOL-R IN PLASTIC CONTAINER).

Breastfeeding	Compatible with breastfeeding. No M/P ratio available; components (electrolytes, lactate) are normal plasma constituents and not excreted in clinically significant amounts.
Teratogenic Risk	No teratogenic risk identified. Normosol-R (an isotonic crystalloid solution) is not associated with fetal malformations. No first-trimester concerns; second and third trimester use is safe for volume resuscitation. No fetal risk known.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperkalemia","Hypersensitivity to any component","Severe metabolic alkalosis","Severe renal impairment with oliguria or anuria"]

Clinical Precautions

Precautions

["Monitor serum electrolytes, fluid balance, and acid-base status","Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hyperkalemia","Risk of fluid overload in patients with compromised cardiovascular function","May cause metabolic alkalosis due to bicarbonate precursors"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NORMOSOL-R IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NORMOSOL-R IN PLASTIC CONTAINER (NORMOSOL-R IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Acetate and gluconate are metabolized primarily in the liver and tissues to bicarbonate.
Excretion	Renal excretion of electrolytes and water; no hepatic metabolism. >95% of administered water and electrolytes are excreted renally, with small amounts lost via feces (<2%) and insensible losses.
Half-life	Not applicable as a drug; the half-life of infused crystalloid components is distribution-dependent. Sodium and chloride have a terminal half-life of approximately 2-4 hours in healthy adults, reflecting renal clearance. Clinical context: Half-life prolonged in renal impairment.
Protein binding	Negligible (<1%) for electrolytes; not bound to plasma proteins.
Volume of Distribution	Sodium and chloride distribute primarily in extracellular fluid (ECF), approximately 0.2 L/kg. Clinical meaning: Expansion of ECF volume; minimal intracellular penetration.
Bioavailability	Intravenous: 100% (complete bioavailability).
Onset of Action	Intravenous: Immediate (within seconds to minutes) as plasma volume expansion and electrolyte correction begin upon infusion.
Duration of Action	Intravenous: 1-2 hours for volume expansion effect; electrolyte effects persist 2-6 hours depending on renal function. Clinical note: Duration is short, requiring continuous infusion for sustained effect.

Classification & Brands

Dosing & administration

Intravenous infusion; dose determined by electrolyte and fluid requirements; typical adult dose: 250-1000 mL/hour, not to exceed 30 mL/kg/day.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with severe renal impairment (GFR <30 mL/min/1.73 m²) due to risk of hyperkalemia and fluid overload. Use with caution and monitor serum potassium and fluid status in moderate impairment (GFR 30-60 mL/min/1.73 m²). No specific dose adjustment; rate and volume should be individualized.
Liver impairment	No specific adjustments for hepatic impairment based on Child-Pugh score; however, monitor fluid and electrolyte balance closely in patients with cirrhosis or ascites due to risk of fluid overload and electrolyte disturbances.
Pediatric use	Dose and rate based on body weight; typical infusion rate: 20-100 mL/kg/day, adjusted for maintenance or replacement needs; monitor serum electrolytes and fluid balance closely.
Geriatric use	Elderly patients may have reduced renal function; start with lower infusion rates and volumes; monitor for fluid overload and electrolyte imbalances, particularly hyperkalemia; adjust based on renal status and cardiac function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NORMOSOL-R IN PLASTIC CONTAINER (NORMOSOL-R IN PLASTIC CONTAINER).

Breastfeeding	Compatible with breastfeeding. No M/P ratio available; components (electrolytes, lactate) are normal plasma constituents and not excreted in clinically significant amounts.
Teratogenic Risk	No teratogenic risk identified. Normosol-R (an isotonic crystalloid solution) is not associated with fetal malformations. No first-trimester concerns; second and third trimester use is safe for volume resuscitation. No fetal risk known.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperkalemia","Hypersensitivity to any component","Severe metabolic alkalosis","Severe renal impairment with oliguria or anuria"]